Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV
Cipepofol is being placed in Schedule IV of the Controlled Substances Act, imposing DEA registration, recordkeeping, and security requirements on manufacturers and handlers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 25, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that manufacture, distribute, or handle cipepofol. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective date not specified in the excerpt; check the full rule for the exact date.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Cipepofol is now a Schedule IV controlled substance, triggering DEA registration, quota, recordkeeping, and security obligations.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that manufacture, distribute, or handle cipepofol.
What you must do
Review current handling of cipepofol and ensure DEA registration is updated or obtained before the effective date.
Deadline
Effective date not specified in the excerpt; check the full rule for the exact date.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
- Determination That CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 Milligrams/6 Milliliters (10 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- PA HB 2749: An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for drug overdose medication.
- US-CONGRESS BILLS-119hr10133ih: Fair Prescription Pricing Act of 2026